Ranibizumab (Lucentis)

Lucentis (ranibizumab) is covered for FDA‑approved indications (neovascular/wet AMD, RVO‑related macular edema, DME, DR, mCNV) and select compendial neovascular ophthalmic uses; uses outside these are not supported. Approval is for up to 12 months, must be administered by or under an ophthalmologist, and requires documentation of diagnosis, indication‑specific intravitreal dosing/frequency (0.5 mg monthly for wet AMD/RVO, 0.3 mg monthly for DME/DR, 0.5 mg monthly for mCNV limited to 3 months) and treatment duration/rationale.

"Macular edema following retinal vein occlusion (RVO)"

Sign up to see full coverage criteria, indications, and limitations.